In vivo olaparib treatment efficiently reduced tumor growth (Figures 7L-7M), consistent with previous reports (Li et al., 2017; Zhang et al., 2018), but also produced a strong desmoplastic response, characterized by enhanced collagen and HA deposition and increased αSMA (Figure 7N). Here, ACTA1 is linked to neoplasm.